Citations

Clear

224 citation(s) found for "Su, Jen-Jen".

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy
Kurokawa, Cheyne, Iankov, Ianko, Anderson, S. Keith , Aderca, Ileana, Leontovich, Alexey A. , Oberg, Ann L. , Greiner, Suzanne , Becker, Marc A., Thompson, E. Aubrey , Haluska, Paul , Jentoft, Mark E. , Weroha, S. John , Jen, Jin , Iankov, Ianko D, Schroeder, Mark A. , Greiner, Suzanne M, Galanis, Evanthia , Maurer, Matthew J. , Giannini, Caterina , Parney, Ian F. , Sarkaria, Jann N.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 6, 2018 | Volume: 110 | Issue: 10 | Pages: 1123-1132

10.1093/jnci/djy033 | PMID 29788332 Get It

Gene Expression Signatures Characterized by Longitudinal Stability and Interindividual Variability Delineate Baseline Phenotypic Groups with Distinct Responses to Immune Stimulation
Scheid, Adam D. , Keulen, Virginia P. Van , Felts, Sara J. , Neier, Steven C. , Middha, Sumit , Nair, Asha, Techentin, Robert W., Gilbert, Barry K., Jen, Jin , Neuhauser, Claudia , Zhang, Yuji , Pease, Larry R. , Van Keulen, Virginia P , Nair, Asha A, Neuhauser, Claudia

Mayo Clinic

The Journal of Immunology | January 19, 2018 | Volume: 200 | Issue: 5 | Pages: 1917-1928

10.4049/jimmunol.1701099 | PMID 29352003 Get It

Abstract Human immunity exhibits remarkable heterogeneity among individuals, which engenders variable responses to immune perturbations in human populations. Population studies reveal that, in addition to interindividual heterogeneity, systemic immune signatures display longitudinal stability within individuals, and these signatures may reliably dictate how given individuals respond to immune perturbations. We hypothesize that analyzing relationships among these signatures at the population level may uncover baseline immune phenotypes that correspond with response outcomes to immune stimuli. To test this, we quantified global gene expression in peripheral blood CD4+ cells from healthy individuals at baseline and following CD3/CD28 stimulation at two time points 1 mo apart. Systemic CD4+ cell baseline and poststimulation molecular immune response signatures (MIRS) were defined by identifying genes expressed at levels that were stable between time points within individuals and differential among individuals in each state. Iterative differential gene expression analyses between all possible phenotypic groupings of at least three individuals using the baseline and stimulated MIRS gene sets revealed shared baseline and response phenotypic groupings, indicating the baseline MIRS contained determinants of immune responsiveness. Furthermore, significant numbers of shared phenotype-defining sets of determinants were identified in baseline data across independent healthy cohorts. Combining the cohorts and repeating the analyses resulted in identification of over 6000 baseline immune phenotypic groups, implying that the MIRS concept may be useful in many immune perturbation contexts. These findings demonstrate that patterns in complex gene expression variability can be used to define immune phenotypes and discover determinants of immune responsiveness.
Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors
Thomas, Charles F., Dong, Jie , Schulte, Sandra C., Khadka, Prasidda , Sun, Zhifu , Kosari, Farhad , Jen, Jin , Molina, Julian R. , Vasmatzis, George , Kuang, Ray, Aubry, Marie Christine, Wigle, Dennis A. , Asiedu, Michael K. , Molina, Julian, Sun, Zhifu , Yang, Ping

Mayo Clinic

Clinical Cancer Research | January 19, 2018 | Volume: 24 | Issue: 7 | Pages: 1691-1704

10.1158/1078-0432.ccr-17-0252 | PMID 29351916 Get It

Abstract Purpose: Pulmonary carcinoid tumors account for up to 5% of all lung malignancies in adults, comprise 30% of all carcinoid malignancies, and are defined histologically as typical carcinoid (TC) and atypical carcinoid (AC) tumors. The role of specific genomic alterations in the pathogenesis of pulmonary carcinoid tumors remains poorly understood. We sought to identify genomic alterations and pathways that are deregulated in these tumors to find novel therapeutic targets for pulmonary carcinoid tumors. Experimental Design: We performed integrated genomic analysis of carcinoid tumors comprising whole genome and exome sequencing, mRNA expression profiling and SNP genotyping of specimens from normal lung, TC and AC, and small cell lung carcinoma (SCLC) to fully represent the lung neuroendocrine tumor spectrum. Results: Analysis of sequencing data found recurrent mutations in cancer genes including ATP1A2, CNNM1, MACF1, RAB38, NF1, RAD51C, TAF1L, EPHB2, POLR3B, and AGFG1. The mutated genes are involved in biological processes including cellular metabolism, cell division cycle, cell death, apoptosis, and immune regulation. The top most significantly mutated genes were TMEM41B, DEFB127, WDYHV1, and TBPL1. Pathway analysis of significantly mutated and cancer driver genes implicated MAPK/ERK and amyloid beta precursor protein (APP) pathways whereas analysis of CNV and gene expression data suggested deregulation of the NF-κB and MAPK/ERK pathways. The mutation signature was predominantly C>T and T>C transitions with a minor contribution of T>G transversions. Conclusions: This study identified mutated genes affecting cancer relevant pathways and biological processes that could provide opportunities for developing targeted therapies for pulmonary carcinoid tumors. Clin Cancer Res; 24(7); 1691–704. ©2018 AACR.
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, Joshua D. , Li, Lu , Wang, Yuxuan , Thoburn, Christopher J. , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A. , Wong, Fay , Mattox, Austin K. , Hruban, Ralph H. , Wolfgang, Christopher L. , Molin, Marco Dal , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Browne, J. Dale, Tie, Jeanne , Wong, Hui‐Li , Mansfield, Aaron S. , Jen, Jin , Falconi, Massimo , Allen, Peter J. , Zhou, Shibin , Díaz, Luis A. , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Thoburn, Christopher , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A , Wong, Fay , Mattox, Austin , Wolfgang, Christopher L , Roden, Richard , Klein, Alison P , Ptak, Janine , Dobbyn, Lisa , Schaefer, Joy , Silliman, Natalie , Schoen, Robert E , Brand, Randall E , Tie, Jeanne , Wong, Hui-Li , Mansfield, Aaron S , Jen, Jin , Zhou, Shibin , Diaz, Luis A , Tomasetti, Cristian , Kinzler, Kenneth W , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Wang, Yuxuan , Afsari, Bahman , Goggins, Michael , Wang, Tian‐Li , Klein, Alison P. , Popoli, Maria , Vogelstein, Joshua T , Schoen, Robert E. , Brand, Randall E. , Gibbs, Peter , Hanash, Samir , Bettegowda, Chetan , Massimo, Falconi

Mayo Clinic

Science | January 18, 2018 | Volume: 359 | Issue: 6378 | Pages: 926-930

10.1126/science.aar3247 | PMID 29348365 Get It

SEEK and you may find cancer earlier Many cancers can be cured by surgery and/or systemic therapies when detected before they have metastasized. This clinical reality, coupled with the growing appreciation that cancer's rapid genetic evolution limits its response to drugs, have fueled interest in methodologies for earlier detection of the disease. Cohen et al. developed a noninvasive blood test, called CancerSEEK that can detect eight common human cancer types (see the Perspective by Kalinich and Haber). The test assesses eight circulating protein biomarkers and tumor-specific mutations in circulating DNA. In a study of 1000 patients previously diagnosed with cancer and 850 healthy control individuals, CancerSEEK detected cancer with a sensitivity of 69 to 98% (depending on cancer type) and 99% specificity. Science , this issue p. 926 ; see also p. 866
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
Gangadhar, Tara C., Hwu, Wen-Jen , Postow, Michael A. , Hamid, Omid , Daud, Adil , Dronca, Roxana , Hodi, F. Stephen , Pavlick, Anna C. , Kluger, Harriet M. , Oxborough, Romina P., Yang, Aiming , Gazdoiu, Mihaela, Kush, Debra, Ebbinghaus, Scot, Salama, April K.S. , Daud, Adil I , Hwu, Wen‐Jen , Joseph, Richard W. , O'Day, Steven J

Mayo Clinic

Journal of Immunotherapy | October 12, 2017 | Volume: 40 | Issue: 9 | Pages: 334-340

10.1097/cji.0000000000000186 | PMID 29028788 Get It

KEYNOTE-030 (ClinicalTrials.gov ID, NCT02083484) was a global expanded access program that allowed access to pembrolizumab, an antiprogrammed death 1 antibody, for patients with advanced melanoma before its regulatory approval. Patients with unresectable stage III/IV melanoma that progressed after standard-of-care therapy, including ipilimumab and, if BRAF V600 mutant, a BRAF inhibitor, were eligible to receive pembrolizumab 2 mg/kg every 3 weeks. Response was assessed by immune-related response criteria by investigator review. Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. In the United States, 979 patients enrolled between April and September 2014. Of the 947 evaluable patients, 621 (65.6%) remained on treatment and transitioned to receive commercial pembrolizumab following approval by the Food and Drug Administration, whereas 326 (34.4%) discontinued, most commonly for disease progression (39.6%) or death (26.4%). Objective response rate was 14.5% (95% confidence interval, 12.2%–16.8%) in the treated population (n=947) and 22.1% (95% confidence interval, 18.8%–25.5%) in patients who had ≥1 response assessment reported (n=619). Twelve patients achieved complete response. One hundred eighty-one (19.1%) patients experienced ≥1 treatment-related AE, most commonly general disorders (8.0%), skin/subcutaneous tissue disorders (7.3%), and gastrointestinal disorders (6.4%); 29 (3.1%) patients experienced ≥1 grade 3/4 treatment-related AE. Immune-mediated AEs were also reported. There were no treatment-related deaths. The safety and efficacy observed in this expanded access program were consistent with those previously reported for similar populations and support the use of pembrolizumab for patients with advanced melanoma.
HPV-related Multiphenotypic Sinonasal Carcinoma
Andreasen, Simon , Hang, Jen‐Fan , Bullock, Martin , Chen, Tiffany , García, Joaquín J. , Gnepp, Douglas R., Gomez‐Fernandez, Carmen , Ihrler, Stephan , Kuo, Ying‐Ju , Lewis, James S. , Magliocca, Kelly R. , Sandison, Ann , Uro‐Coste, Emmanuelle , Stelow, Edward B. , Kiss, Katalin , Westra, William H. , Bishop, Justin A. , Franchi, Alessandro , Pambuccian, Stefan E.

Mayo Clinic

American Journal of Surgical Pathology | September 6, 2017 | Volume: 41 | Issue: 12 | Pages: 1690-1701

10.1097/pas.0000000000000944 | PMID 28877065 Get It

Human papillomavirus (HPV)–related multiphenotypic sinonasal carcinoma (HMSC), originally known as HPV-related carcinoma with adenoid cystic carcinoma-like features, is a peculiar neoplasm that is restricted to the sinonasal tract, exhibits features of both a surface-derived and salivary gland carcinoma (particularly adenoid cystic carcinoma), and is associated with high-risk HPV. Given the limited number of published cases, the full clinicopathologic spectrum of this neoplasm is unclear. Here, we present an updated experience of 49 cases. All cases of HMSC were obtained from the authors’ files. Immunohistochemistry for p16, c-kit, and myoepithelial cell markers (S100, actin, calponin, p63, and/or p40) was performed along with RNA in situ hybridization for HPV (type 33-specific as well as a high-risk cocktail). Fluorescence in situ hybridization studies for fusions ofMYB,NFIB, andMYBL1was performed on a subset of cases. Clinical follow-up was obtained from medical records. A total of 49 cases of HMSC were collected. Twenty-eight (57%) were from women and 18 (43%) from men, ranging in age from 28 to 90 years (mean, 54 y). Of 40 cases with detailed staging information, 43% of HMSCs presented with a high T-stage (T3 or T4). Histologically, most grew predominantly as solid nests of basaloid cells exhibiting high mitotic rates and frequent necrosis, with histologic and immunohistochemical evidence of myoepithelial differentiation. Most cases also demonstrated foci of cribriform and/or tubular growth, along with an inconspicuous population of ducts. Thirty-four (69%) cases demonstrated an unusual pattern of surface involvement where markedly atypical squamous cells colonized tracts of the sinonasal mucosa. Less consistent histologic features included squamous differentiation within the invasive tumor (n=6), sarcomatoid transformation (n=5) including overt chondroid differentiation (n=3), and prominent epithelial-myoepithelial carcinoma-like growth (n=3). All cases were positive for p16 by immunostaining and HPV by RNA in situ hybridization. Thirty-three (67%) were positive for HPV 33. No cases tested forMYB,MYBL1, orNFIBgene fusions were positive. In the 38 cases with follow-up data, (mean follow-up, 42 mo) 14 recurred locally and 2 metastasized (lung, finger). There were no regional lymph node metastases, and no tumor-related deaths. HMSC is a distinct sinonasal neoplasm characterized by myoepithelial differentiation, frequent surface epithelial involvement, and the presence of high-risk HPV (especially type 33). Although it classically exhibits a cribriforming pattern that closely resembles adenoid cystic carcinoma, our expanded series highlights a histologic spectrum that is much broader than previously recognized, warranting a change in terminology. HMSC usually presents as a large and destructive sinonasal mass with high-grade histologic features, but it paradoxically behaves in a relatively indolent manner, underscoring the importance of distinguishing HMSC from true adenoid cystic carcinoma, squamous cell carcinoma, and other histologic mimickers.
TARGETABLE FUSIONS OF THE FRK TYROSINE KINASE IN ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA
Boddicker, Rebecca L., Dasari, Surendra , Asmann, Yan W. , Knudson, Ryan A., Eckloff, Bruce W., Jen, Jin , Hu, Gangqing , Greipp, Patricia T. , Link, Brian K. , Bennani, N. Nora , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 59-59

10.1002/hon.2437_45 Get It

Meeting Report of the Fifth International Cancer Epigenetics Conference in Beijing, China, October 2016
Gao, Dan , Herman, James G. , Cui, Hengmi , Jen, Jin , Fuks, François , Brock, Malcolm V., Ushijima, Toshikazu , Guo, Mingzhou , Croce, Carlo Maria , Akiyama, Yoshimitsu

Mayo Clinic

Epigenomics | May 22, 2017 | Volume: 9 | Issue: 7 | Pages: 937-941

10.2217/epi-2017-0030 | PMID 28530839 Get It

Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Ho, Yeung, Etten, Jamie L. Van, Yang, Rendong , Li, Yingming , Tseng, Elizabeth , Hon, Ting, Clark, Tyson A. , Tan, Winston , Carlson, Rachel E. , Wang, Liguo , Sicotte, Hugues , Ho, Thai H. , Jiménez, Rafael E. , Vedell, Peter T. , Eckloff, Bruce W., Quevedo, J. Fernando , Pitot, Henry C., Costello, Brian A. , Jen, Jin , Wieben, Eric D. , Silverstein, Kevin A.T. , Wang, Liewei , Dehm, Scott M. , Kohli, Manish , Thai, Ho, Jimenez, Rafael, Quevedo, Jorge F, Hillman, David W. , Henzler, Christine M. , Sperger, Jamie M. , Huang, Haojie , Lang, Joshua M. , Ho, Thai , Wang, Liguo , Dehm, Scott M

Mayo Clinic

Clinical Cancer Research | May 4, 2017 | Volume: 23 | Issue: 16 | Pages: 4704-4715

10.1158/1078-0432.ccr-17-0017 | PMID 28473535 Get It

Abstract Purpose: Androgen receptor (AR) variant AR-V7 is a ligand-independent transcription factor that promotes prostate cancer resistance to AR-targeted therapies. Accordingly, efforts are under way to develop strategies for monitoring and inhibiting AR-V7 in castration-resistant prostate cancer (CRPC). The purpose of this study was to understand whether other AR variants may be coexpressed with AR-V7 and promote resistance to AR-targeted therapies. Experimental Design: We utilized complementary short- and long-read sequencing of intact AR mRNA isoforms to characterize AR expression in CRPC models. Coexpression of AR-V7 and AR-V9 mRNA in CRPC metastases and circulating tumor cells was assessed by RNA-seq and RT-PCR, respectively. Expression of AR-V9 protein in CRPC models was evaluated with polyclonal antisera. Multivariate analysis was performed to test whether AR variant mRNA expression in metastatic tissues was associated with a 12-week progression-free survival endpoint in a prospective clinical trial of 78 CRPC-stage patients initiating therapy with the androgen synthesis inhibitor, abiraterone acetate. Results: AR-V9 was frequently coexpressed with AR-V7. Both AR variant species were found to share a common 3′ terminal cryptic exon, which rendered AR-V9 susceptible to experimental manipulations that were previously thought to target AR-V7 uniquely. AR-V9 promoted ligand-independent growth of prostate cancer cells. High AR-V9 mRNA expression in CRPC metastases was predictive of primary resistance to abiraterone acetate (HR = 4.0; 95% confidence interval, 1.31–12.2; P = 0.02). Conclusions: AR-V9 may be an important component of therapeutic resistance in CRPC. Clin Cancer Res; 23(16); 4704–15. ©2017 AACR.